查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1589176

皮质类固醇治疗市场：按类型、给药途径和应用分类 - 2025-2030 年全球预测

Corticosteroids Therapy Market by Type (Glucocorticoids, Mineralocorticoids), Route of Administration (Inhaled, Oral, Systemic), Application - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年皮质类固醇治疗市值为49.7亿美元，预计到2024年将达到52.6亿美元，复合年增长率为7.48%，预计到2030年将达到82.4亿美元。

皮质类固醇疗法使用模仿皮质醇（肾上腺皮质自然分泌的荷尔蒙）的合成药物来减少发炎并抑制免疫系统。皮质类固醇对于治疗关节炎、过敏反应、气喘、自体免疫疾病，甚至某些癌症等许多疾病至关重要，这表明它们在医疗干预中的必要性。这些药物可局部、局部或静脉注射，最终用途主要在医疗机构，如医院和诊所、製药公司和研究型大学。市场成长要素包括慢性病盛行率上升、对自体免疫疾病的认识不断提高以及药物传递系统的进步。此外，扩大新兴国家的医疗基础设施也带来了利润丰厚的机会。然而，感染风险增加和潜在副作用（例如长期使用导致骨质疏鬆）、监管挑战和抗药性开拓等挑战可能会阻碍市场成长。为了利用这些机会，公司应该专注于开发具有改进的安全性和个人化医疗方法的皮质类固醇。新型药物输送系统（例如吸入器和经皮吸收贴片）的创新有可能提高疗效并最大限度地减少副作用。此外，皮质类固醇非基因组途径的研究可能为创新治疗铺路。与研究机构的策略联盟可以丰富产品平臺并加速进展。您还可以透过监控法规变更并敏捷地回应合规性来获得竞争优势。皮质类固醇治疗市场充满活力，与医疗保健政策和科学创新的波动密切相关。公司需要在研发方面采取积极主动的方法，专注于基因对齐治疗方法，并利用数位健康技术来支持个人化治疗策略。透过有效克服挑战并抓住对客製化医疗保健解决方案不断增长的需求，公司可以在这个不断发展的市场中维持和扩大成长。

主要市场统计
基准年[2023] 49.7亿美元
预测年份 [2024] 52.6亿美元
预测年份 [2030] 82.4亿美元
复合年增长率（%） 7.48%

市场动态：快速发展的皮质类固醇治疗市场的关键市场洞察

供需的动态交互作用正在改变皮质类固醇治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助消费行为及其对製造业的影响。

  • 市场驱动因素
    • 发炎和自体免疫疾病的盛行率增加
    • 药物传输系统的可用性提高了便利性和有效性
    • 皮质类固醇在感染疾病治疗的应用
  • 市场限制因素
    • 替代治疗的可用性
  • 市场机会
    • 介绍一种新型可注射载体皮质类固醇疗法
    • 改善单吸入性皮质类固醇治疗
  • 市场挑战
    • 与皮质类固醇治疗相关的副作用

波特的五力：驾驭皮质类固醇治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解皮质类固醇治疗市场的外部影响

外部宏观环境因素在塑造皮质类固醇治疗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解皮质类固醇治疗市场的竞争格局

对皮质类固醇治疗市场的详细市场占有率分析可以对供应商的表现进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV 定位矩阵皮质类固醇治疗市场供应商的绩效评估

FPNV定位矩阵是评估皮质类固醇治疗市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了皮质类固醇治疗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，皮质类固醇治疗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，以帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 发炎和自体免疫疾病的盛行率增加
      • 药物传输系统的可用性提高了便利性和有效性
      • 皮质类固醇疗法在感染疾病的治疗应用
    • 抑制因素
      • 替代治疗的可用性
    • 机会
      • 介绍一种新型可注射载体皮质类固醇疗法
      • 改善单药吸入类固醇治疗
    • 任务
      • 与皮质类固醇治疗相关的副作用
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章皮质类固醇治疗市场：依类型

  • 糖皮质激素
  • 盐皮质激素

第七章皮质类固醇治疗市场：依给药途径

  • 吸入
  • 口服
  • 系统性的
  • 话题

第八章皮质类固醇治疗市场：依应用分类

  • 急性呼吸道疾病
  • 内分泌学
  • 胃肠病学
  • 风湿病学
  • 皮肤过敏

第九章美洲皮质类固醇治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太皮质类固醇治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲的皮质类固醇治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abbott Laboratories
  • Allergan PLC by AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Biogen Inc.
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Dr. Reddy's Laboratories Ltd.
  • Eli Lilly and Company
  • Galderma Group
  • Gilead Sciences, Inc.
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • SANTHERA PHARMACEUTICALS
  • Sun Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
Product Code: MRR-C002B1C9976A

The Corticosteroids Therapy Market was valued at USD 4.97 billion in 2023, expected to reach USD 5.26 billion in 2024, and is projected to grow at a CAGR of 7.48%, to USD 8.24 billion by 2030.

Corticosteroid therapy involves using synthetic drugs that mimic cortisol-a hormone naturally produced by the adrenal cortex, to reduce inflammation and suppress the immune system. They are critical in treating numerous conditions like arthritis, allergic reactions, asthma, autoimmune disorders, and even certain cancers, underscoring their necessity in medical interventions. These drugs are applied topically, orally, or intravenously and find end-use primarily in healthcare institutions such as hospitals and clinics, pharmaceuticals, and research universities. Market growth factors include the rising prevalence of chronic diseases, increasing awareness about autoimmune diseases, and advancements in drug delivery systems. Furthermore, expansions in healthcare infrastructure in emerging economies present lucrative opportunities. However, challenges such as potential side effects, like increased risk of infection and weakening of bones upon prolonged use, regulatory challenges, and the development of drug resistance may impede market growth. To capitalize on these opportunities, businesses should focus on developing corticosteroids with improved safety profiles and personalized medicine approaches. Innovations in novel drug delivery systems, like inhalers or transdermal patches, could enhance efficacy and minimize side effects. Furthermore, research into non-genomic pathways of corticosteroids could pave the way for innovative therapies. Strategic collaborations with research institutions could enrich product pipelines and accelerate advancements. Monitoring regulatory changes and being agile in compliance can also provide competitive advantages. The corticosteroid therapy market is dynamic, closely tied to fluctuations in healthcare policies and scientific innovations. Companies need to adopt a proactive approach in research and development, focusing on genetically aligned treatments and leveraging digital health technologies to support personalized therapeutic strategies. By effectively navigating the challenges and tapping into the growing demand for tailored healthcare solutions, companies can sustain growth and expand within this evolving market.

KEY MARKET STATISTICS
Base Year [2023] USD 4.97 billion
Estimated Year [2024] USD 5.26 billion
Forecast Year [2030] USD 8.24 billion
CAGR (%) 7.48%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Corticosteroids Therapy Market

The Corticosteroids Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of inflammatory and autoimmune diseases
    • Availability of drug delivery systems with improved convenience and efficacy
    • Therapeutic applications of corticosteroids-therapy in infectious diseases
  • Market Restraints
    • Availability of alternative therapies
  • Market Opportunities
    • Introduction of novel injectable carrier-based corticosteroid therapy
    • Improvements in single-entity inhaled corticosteroid therapy
  • Market Challenges
    • Adverse effects associated with corticosteroids-therapy

Porter's Five Forces: A Strategic Tool for Navigating the Corticosteroids Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Corticosteroids Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Corticosteroids Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Corticosteroids Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Corticosteroids Therapy Market

A detailed market share analysis in the Corticosteroids Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Corticosteroids Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Corticosteroids Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Corticosteroids Therapy Market

A strategic analysis of the Corticosteroids Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Corticosteroids Therapy Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Allergan PLC by AbbVie Inc., Amgen Inc., AstraZeneca PLC, Biogen Inc., Boehringer Ingelheim GmbH, Bristol-Myers Squibb Company, Cipla Inc., Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, Galderma Group, Gilead Sciences, Inc., GlaxoSmithKline PLC, Lupin Pharmaceuticals, Inc., Merck & Co., Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., SANTHERA PHARMACEUTICALS, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Corticosteroids Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Glucocorticoids and Mineralocorticoids.
  • Based on Route of Administration, market is studied across Inhaled, Oral, Systemic, and Topical.
  • Based on Application, market is studied across Acute Respiratory Diseases, Endocrinology, Gastroenterology, Rheumatology, and Skin Allergies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of inflammatory and autoimmune diseases
      • 5.1.1.2. Availability of drug delivery systems with improved convenience and efficacy
      • 5.1.1.3. Therapeutic applications of corticosteroids-therapy in infectious diseases
    • 5.1.2. Restraints
      • 5.1.2.1. Availability of alternative therapies
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel injectable carrier-based corticosteroid therapy
      • 5.1.3.2. Improvements in single-entity inhaled corticosteroid therapy
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with corticosteroids-therapy
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Corticosteroids Therapy Market, by Type

  • 6.1. Introduction
  • 6.2. Glucocorticoids
  • 6.3. Mineralocorticoids

7. Corticosteroids Therapy Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Inhaled
  • 7.3. Oral
  • 7.4. Systemic
  • 7.5. Topical

8. Corticosteroids Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Acute Respiratory Diseases
  • 8.3. Endocrinology
  • 8.4. Gastroenterology
  • 8.5. Rheumatology
  • 8.6. Skin Allergies

9. Americas Corticosteroids Therapy Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Corticosteroids Therapy Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Corticosteroids Therapy Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. Allergan PLC by AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Biogen Inc.
  • 6. Boehringer Ingelheim GmbH
  • 7. Bristol-Myers Squibb Company
  • 8. Cipla Inc.
  • 9. Dr. Reddy's Laboratories Ltd.
  • 10. Eli Lilly and Company
  • 11. Galderma Group
  • 12. Gilead Sciences, Inc.
  • 13. GlaxoSmithKline PLC
  • 14. Lupin Pharmaceuticals, Inc.
  • 15. Merck & Co., Inc.
  • 16. Mylan N.V.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Sanofi S.A.
  • 20. SANTHERA PHARMACEUTICALS
  • 21. Sun Pharmaceutical Industries Ltd.
  • 22. Takeda Pharmaceutical Company Limited
  • 23. Teva Pharmaceutical Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. CORTICOSTEROIDS THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CORTICOSTEROIDS THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CORTICOSTEROIDS THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CORTICOSTEROIDS THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GLUCOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY MINERALOCORTICOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY INHALED, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SYSTEMIC, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TOPICAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ACUTE RESPIRATORY DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ENDOCRINOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY GASTROENTEROLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY RHEUMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CORTICOSTEROIDS THERAPY MARKET SIZE, BY SKIN ALLERGIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 25. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 28. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 31. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 32. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 33. CANADA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 36. MEXICO CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 37. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 39. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. UNITED STATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 41. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 42. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 43. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. ASIA-PACIFIC CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 45. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 46. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. AUSTRALIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 50. CHINA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. INDIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 55. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 56. INDONESIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 57. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. JAPAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 62. MALAYSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. PHILIPPINES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. SINGAPORE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 71. SOUTH KOREA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 74. TAIWAN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 77. THAILAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 79. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 80. VIETNAM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 85. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 87. DENMARK CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 90. EGYPT CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 93. FINLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 96. FRANCE CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 99. GERMANY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 102. ISRAEL CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 104. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 105. ITALY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 106. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 108. NETHERLANDS CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 111. NIGERIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 113. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 114. NORWAY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 116. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 117. POLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 118. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 120. QATAR CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 123. RUSSIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 124. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. SAUDI ARABIA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH AFRICA CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 130. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 131. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 132. SPAIN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 135. SWEDEN CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 137. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 138. SWITZERLAND CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 139. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 140. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 141. TURKEY CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 142. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 143. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 144. UNITED ARAB EMIRATES CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 147. UNITED KINGDOM CORTICOSTEROIDS THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 148. CORTICOSTEROIDS THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 149. CORTICOSTEROIDS THERAPY MARKET, FPNV POSITIONING MATRIX, 2023